Eosinophilic Esophagitis Indication Strategy Report 2026: IL-13, IL-5, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Chronic Spontaneous Urticaria Indication Strategy Report 2026: IgE, BTK, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Vitiligo Indication Strategy Report 2026: IFN-γ, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Alopecia Areata Indication Strategy Report 2026: JAK1, JAK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Hidradenitis Suppurativa Indication Strategy Report 2026: TNF, IL-17, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Systemic Sclerosis Indication Strategy Report 2026: IL-6, TGF-β, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Sjogren Syndrome Indication Strategy Report 2026: BAFF, CD40L, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Systemic Lupus Erythematosus Indication Strategy Report 2026: BAFF, CD19, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Rheumatoid Arthritis Indication Strategy Report 2026: TNF, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Psoriatic Arthritis Indication Strategy Report 2026: IL-17, TYK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Plaque Psoriasis Indication Strategy Report 2026: IL-17, IL-23, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Crohn Disease Indication Strategy Report 2026: TNF, IL-23, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.